<DOC>
	<DOCNO>NCT00454896</DOCNO>
	<brief_summary>The purpose evaluate efficacy 5 10mg VESIcare® ( solifenacin succinate ) patient urgency overactive bladder syndrome .</brief_summary>
	<brief_title>A Multicenter VESIcare® Efficacy Safety Study Treatment Urgency Associated With Overactive Bladder ( OAB )</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>At least 1 urinary urgency episode/24h ( average ) document 3day patient diary screening phase without urge incontinence , usually frequency nocturia , describe OAB Patients may include never expose anticholinergic agent specify treatment OAB . Patients may also include previously treat FDAapproved anticholinergic agent treatment OAB oxybutynin chloride longer receive treatment minimum 14 day immediately precede entry study . These previously treat patient must present investigative site anticholinergic agent desire receive treatment OAB . Previous nondrug treatment OAB allow establish least 4 week prior study entry continue throughout study . Patients urgency without urge incontinence accompany frequency ≥8 episodes per 24 hour , and/or nocturia , period ≥3 month prior screen . Previous treatment darifenacin Duration urgency without urge incontinence , usually accompany frequency nocturia &lt; 3 month Significant stress incontinence mixed stress/urge incontinence stress predominant factor determine Investigator Evidence urinary tract infection ; chronic inflammation interstitial cystitis bladder stone Clinically significant outflow obstruction ( benign prostatic hyperplasia ) determine Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Urinary Bladder , Overactive</keyword>
	<keyword>Urgency</keyword>
	<keyword>VESIcare®</keyword>
	<keyword>Solifenacin succinate</keyword>
</DOC>